Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchase of marketable securities | (174,893,062) | (18,181,600) |
| Proceeds from sales and maturities of marketable securities | 30,998,448 | 43,212,559 |
| Purchases of property and equipment | (5,121,709) | (896,007) |
| Payments for leasehold improvements | (921,752) | (244,279) |
| Payments for construction in progress | (4,703,521) | — |
| Net cash provided by (used in) investing activities | (154,641,596) | 23,890,673 |
| Cash flows from financing activities: |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's capex?
- Capricor Therapeutics (CAPR) reported capex of $5.12M in Q1 2026.
- How has Capricor Therapeutics's capex changed year-over-year?
- Capricor Therapeutics's capex increased by 471.6% year-over-year, from $896.01K to $5.12M.
- What is the long-term trend for Capricor Therapeutics's capex?
- Over 4 years (2021 to 2025), Capricor Therapeutics's capex has grown at a 24.8% compound annual growth rate (CAGR), from $1.2M to $2.9M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Capricor Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude